•
PL
PLRX
Pliant Therapeutics, Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
77.43M
Volume
1.03M
52W High
$12.88
52W Low
$1.10
Open
$0.00
Prev Close
$1.28
Day Range
0.00 - 0.00
About Pliant Therapeutics, Inc. Common Stock
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Latest News
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
GlobeNewswire Inc.•Mar 23
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
GlobeNewswire Inc.•Feb 7
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
GlobeNewswire Inc.•Nov 18
Pliant Therapeutics CBO sells shares worth over $114k - Investing.com
Investing.com•Jul 13
These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings
Benzinga•May 7
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
Zacks Investment Research•Mar 7
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga•Feb 5
HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know
Benzinga•Feb 5